Icp Pre-screening System
Icp Pre-screening System - Related Videos
02:01
pre-mRNA Processing
0 Views •
2019
In eukaryotic cells, transcripts made by RNA polymerase are modified and processed before exiting the nucleus. Unprocessed RNA is called precursor mRNA or pre-mRNA to distinguish it from mature mRNA. Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a “cap” to the 5’ end of the growing transcript. In this process, a 5’ phosphate is replaced by modified guanosine that has a methyl group attached to it (7-Methyl guanosine). This 5’ cap helps the...
01:20
Inductively Coupled Plasma-Mass Spectrometry (ICP-MS): Interferences
0 Views •
2024
Inductively coupled plasma–mass spectrometry (ICP–MS) is a highly selective and sensitive technique for accurate elemental analysis. Though the analysis of ICP–MS mass spectra is comparatively straightforward, it is affected by spectroscopic and non-spectroscopic interferences. Spectroscopic interferences arise when the plasma contains ionic species with an m/z value the same as the analyte ion. Spectroscopic interference can be categorized as isobaric, polyatomic ions, and refractory oxide ion...
01:35
Pre-mRNA Processing: Modification of pre-mRNA Ends
0 Views •
2023
In eukaryotic cells, transcripts made by RNA polymerase are modified and processed before exiting the nucleus. Unprocessed RNA is called precursor mRNA or pre-mRNA to distinguish it from mature mRNA. Once about 20-40 ribonucleotides have been joined together by RNA polymerase, a group of enzymes adds a cap to the 5' end of the growing transcript. In this process, a 5' phosphate is replaced by modified guanosine that has a methyl group attached (7-methyl guanosine). This 5' cap helps the cell...
01:19
Inductively Coupled Plasma–Mass Spectrometry (ICP–MS): Overview
0 Views •
2024
In inductively coupled plasma–mass spectrometry (ICP–MS), an inductively coupled plasma (ICP) torch is used as an atomizer and ionizer. Solid samples are dissolved and volatilized before being introduced into the high-temperature argon plasma, while solution samples are nebulized and passed through the high-temperature argon plasma. Plasma dissociates the analytes and ionizes their component atoms to form a mixture of positive ions and molecular species. The positive ions are then passed on to...
09:51
Standards for Quantitative Metalloproteomic Analysis Using Size Exclusion ICP-MS
0 Views •
Cited by 34 •
2016
Size exclusion chromatography hyphenated with inductively coupled plasma - mass spectrometry (ICP-MS) is a powerful tool to measure changes in the abundance of metalloproteins directly from biological samples. Here we describe a set of metalloprotein standards used to estimate molecular mass and the amount of metal associated with unknown proteins.
FAQs
The system integrates clinical signs with noninvasive measurements or imaging findings rather than relying on a single observation. This combined assessment can strengthen concern when multiple findings point toward pressure-related changes and can help clinicians decide whether a patient requires more detailed evaluation. Its value lies in organizing early evidence for triage, not replacing confirmatory assessment.
Elevated intracranial pressure can reduce cerebral perfusion, meaning the brain may receive less effective blood flow, and can threaten neurological function. For this reason, pre-screening focuses on findings that may signal pressure-related compromise before deterioration becomes more apparent. Recognizing this risk supports earlier escalation, monitoring, and clinical decision-making.
Pre-screening identifies patients who may need further assessment, whereas confirmatory testing is used to evaluate the concern in greater detail. The preliminary approach can help clinicians prioritize patients and avoid unnecessary invasive procedures when the available findings do not suggest sufficient concern. It therefore functions as a decision-support step rather than a final determination.
The approach is relevant when pressure-related neurological risk may accompany traumatic brain injury, stroke, hydrocephalus, or intracranial hemorrhage. These conditions provide different clinical contexts in which early screening may help identify patients needing closer evaluation. Applying the system across these settings supports timely triage while keeping the assessment focused on possible effects of raised intracranial pressure.
Clinicians first review relevant clinical signs, then consider available noninvasive measurements or imaging findings for evidence of pressure-related change. They combine these observations to determine whether further assessment is warranted and use the result to guide triage or monitoring. If concern remains, the patient can proceed to appropriate confirmatory testing or intervention according to the clinical situation.
It is most useful when clinicians must make an early decision about neurological risk and the need for additional evaluation. In traumatic brain injury, stroke, hydrocephalus, or intracranial hemorrhage, the system can help identify patients who may require closer monitoring or timely confirmation. This supports prioritization while potentially reducing unnecessary invasive procedures.
The system can support earlier recognition of patients who may have dangerous pressure-related changes, more focused triage, and decisions about confirmatory testing. It may also guide monitoring and help limit invasive procedures when preliminary evidence does not justify them. Its practical outcome is improved organization of early clinical decisions, while definitive management still depends on further assessment.